Qualifying Comorbidities FDA labeling and clinical guidelines commonly recognize: Hypertension (blood pressure 130/80 or taking antihypertensive medication) Type 2 diabetes (HbA1c 6.5% or on glucose-lowering medication) Prediabetes (HbA1c 5.7-6.4% or impaired fasting glucose) Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides) Obstructive sleep apnea (diagnosed via sleep study) Cardiovascular disease (prior MI, stroke, coronary artery disease) Non-alcoholic fatty liver disease / MASLD Polycystic ovary syndrome (PCOS) with metabolic features Osteoarthritis weight-bearing joints Insurance formularies may be stricter some require objective documentation (lab values, sleep study reports) rather than self-report
Semaglutide GLP-1 injections have been shown to reduce the risk of major cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes
GHK-Cu downregulates acute-phase and pro-inflammatory cytokines (TNF-?, IL-6), upregulates anti-oxidant defenses (including superoxide dismutase, Nrf2 and HO-1 pathways), and suppresses fibrotic signaling by inhibiting TGF-?1/Smad2/3 activation
These injections can help you feel fuller with smaller portions, making it easier to stay on track
Potential Side Effects Like any medication, Zepbound (tirzepatide) may have side effects